Tau Capital has cut the value of Stopharm again and will now vale this investment at $8m. Tau Capital say the devaluation of the Tenge in February made Stopharm’s imports of pharmaceuticals (most of which are priced in euros or US dollars) more expensive without automatically allowing it to raise prices in Tenge as sales prices in Kazakhstan tend to be fixed for 12 months.
